ModifiedBlue Cross Blue Shield - North CarolinaPolicy AHS - R2162
Laboratory Procedures Medical Policy
Customize your policy alerts
Sign up for Blue Cross Blue Shield - North Carolina Policy AHS - R2162 alerts
Get alerted when Policy AHS - R2162 changes without checking for updates manually.
Monitor payer policy activity
Receive email alerts as soon as relevant payer policies are published or updated.
Defines BCBSNC reimbursement rules, coding and billing guidelines, and edits for outpatient laboratory procedures for providers submitting claims to Blue Cross Blue Shield of North Carolina.
Policy Summary
PayerBlue Cross Blue Shield - North Carolina
PolicyLaboratory Procedures Medical Policy
Policy CodePolicy AHS - R2162
Change TypeCoding additions and clarification of panel and unit threshold rules
Effective DateMay 6, 2026
Last ReviewMay 6, 2026
Next Review DateJan 1, 2026
Key ActionSubmit outpatient laboratory claims per AMA CPT/HCPCS and ICD-10 guidelines and provide medical records when requested to support medical necessity.
SourceLink
POLICY UPDATE CHANGES
Updated statement on concurrent ordering for clarity and added new repeat multi-gene panel testing requirements and related coding/billing updates.
Added numerous PLA codes and other procedure codes to the Billing/Coding section (multiple effective dates through 7/1/26).
2026-05-06Effective date
01/2019Origination
70+Service codes listed
~150+Procedure codes in section
One81479 unit max
OneConcurrent panel orders
Coverage and Reimbursement Criteria
Reimbursement criteria and billing rules
BCBSNC will reimburse laboratory procedures when billing and medical necessity criteria are met and benefits apply per member's benefit determination.
Claims must comply with AMA CPT/HCPCS and ICD-10 coding and regulatory guidelines; additional policy requirements may apply.
Reimbursement is subject to member benefit availability — review the Member's Benefit Booklet before applying policy terms.
BCBSNC may request medical records and documentation to determine medical necessity; letters of support alone are insufficient unless they include all required specific information.
Medical records may be requested to determine medical necessity; letters of support/explanation are not sufficient unless all specific information is included.
If incorrect codes are submitted to represent panel testing, reimbursement is not allowed for all codes submitted due to incorrect coding process.
Certain CPT/HCPCS codes are non-reimbursable (e.g., older AMA drug assay codes 80320-80377; PLA/unlisted codes not reimbursed when a specific Tier 1/2/GSP/MAAA/PLA code exists or per applicable policy).
If there is not a specific next-generation sequencing (NGS) procedure code that represents the requested test, a maximum of ONE unit of 81479 may be billed.
Edit-based denials may occur for exclusivity (duplicate components/panels), incorrect diagnosis codes, incorrect patient age, incorrect place of service, once-per-lifetime tests, and unit threshold exceedances.
Modifier rules must be followed: verify -26/-TC usage, -90 may be used only as permitted, -91 for repeat testing per policy, and QW required for CLIA‑waived tests.
Coverage criteria and rules
Coverage and reimbursement are subject to coding accuracy, unit limits, panel rules, and medical necessity documentation.
If a procedure code assigned a maximum unit value is reported with a greater unit count, the claim line will be reimbursed only for the number of units up to but not exceeding the allowed maximum.per CPT/HCPCS description, policy, or third-party limits
If incorrect codes are submitted to represent panel testing, reimbursement is not allowed for ALL codes submitted due to incorrect coding process.
If there is not a specific NGS procedure code that represents the requested test, a maximum of ONE unit of 81479 may be billed.
Concurrent ordering of multi-gene panel tests for a specific condition is strictly prohibited: only one multi-gene panel test may be ordered at a time for a specific condition.
Repeat multi-gene panel testing is not allowed unless ALL of the following are true: the individual met all necessary criteria to receive genetic panel testing; the individual does not have a previously identified causative mutation for the disorder being evaluated; and the requested panel contains one or more genes previously untested.
BCBSNC may request medical records for determination of medical necessity; requested documentation must include all specific information needed to make a determination.
Inclusion of a code in the Billing/Coding section does not guarantee reimbursement; see administrative policies for further reimbursement guidance.
Billing, Codes, and Unit Rules
Listed procedure/code guidanceCPT
| 0331U-0656U (selected U-codes listed) | Applicable service codes enumerated in the policy; inclusion does not guarantee reimbursement. |
| 80320-80377 | AMA drug assay codes not accepted; refer to alternate G0480-G0483 per other policy. |
| 81479, 81599, 84999 | Unlisted codes not accepted if a specific Tier 1/2/GSP/MAAA/PLA code exists. |
Applicable service codes (select examples and NGS guidance)mixed
| 0331U | PLA/procedure code listed in Billing/Coding section |
| 0341U | PLA/procedure code listed in Billing/Coding section |
| 0614U | PLA/procedure code added effective 4/1/26 |
| 0635U | PLA/procedure code added effective 7/1/26 |
| 81479 | Unlisted molecular pathology procedure (maximum ONE unit may be billed when no specific NGS code exists) |
Maximum units per code
Reimbursement capClaims are reimbursed up to the allowed maximum units per date of service or historical thresholds as determined by CPT/HCPCS description, medical policy, or third‑party limits.
Determination sourcesMaximum units may be defined by CPT/HCPCS code description, laboratory coverage guidelines in medical policy, anatomical/clinical limitations, scientific/statistical analyses, or third‑party (CCI/CMMS) limits.
Excess billed unitsIf billed units exceed the assigned maximum, the claim line will be reimbursed only for units up to but not exceeding the allowed maximum.
Multi-gene panel units
81479 unit limit for panelsIf no specific NGS procedure code represents the requested multi‑gene panel test, a maximum of ONE unit of CPT 81479 may be billed.
Panel code preferenceWhen a specific multi‑gene panel procedure code exists (e.g., 81442), that code must be used instead of unlisted codes.
Documentation requirementAll gene tests in the panel must be listed on the request and the ordering provider must justify clinical utility.
Once-per-lifetime limitation
Once‑per‑lifetime ruleCertain laboratory services/procedure codes are limited to once in a patient’s lifetime; subsequent submissions will not be reimbursed.
Edit invocationThe once‑per‑lifetime edit enforces frequency limits defined in medical policy for applicable codes.
Provider implicationIf a once‑per‑lifetime test is billed more than once, only the initial submission is eligible for reimbursement.
Unit maximum per procedure
Per‑procedure unit maximumWhen a procedure code has an assigned maximum unit value, claims are reimbursed only for units up to that allowed maximum per DOS or time period.
Operational triggersUnit threshold edits trigger when units billed on a single DOS or over a period exceed allowed reimbursement quantities regardless of individual clinical context.
Sources for limitsLimits derived from code description, policy guidelines, anatomical/clinical constraints, analyses, or third‑party rules.
81479 billing limit
81479 single‑unit ruleCPT 81479 (unlisted molecular pathology) may be billed for a multi‑gene NGS panel only as a maximum of ONE unit when no specific NGS code exists.
Not a substitute for specific codesIf a specific NGS procedure code exists for the panel, that code must be used instead of 81479.
Incorrect coding consequenceIf incorrect codes are submitted to represent panel testing, reimbursement is not allowed for all codes submitted due to incorrect coding process.
Claims Submission and Documentation Requirements
Billing Rule
Claim submission and documentation
To be considered for reimbursement, submit all outpatient laboratory claims in accordance with AMA CPT and HCPCS coding and ICD-10 diagnosis coding guidelines, other laboratory/pathology coding guidelines, and all applicable regulatory guidelines. Inclusion of a code in the Billing/Coding section does not guarantee reimbursement; review Administrative Policies on the BCBSNC website for further reimbursement guidance. BCBSNC may request medical records to determine medical necessity and may audit or request documentation as part of claims review.
- Follow AMA CPT/HCPCS and ICD-10 coding guidelines when preparing claims.
- Ensure claims reflect any additional policy requirements outlined in this document and in BCBSNC Administrative Policies.
- Be prepared to provide supporting medical records if requested for claims review or audit.
Documentation Required
Medical records request for medical necessity — documentation required
BCBSNC may request medical records to determine medical necessity; when records are requested, letters of support or explanation are not sufficient unless they include all specific information required to make the medical necessity determination. Maintain and produce full clinical documentation when requested; failure to provide complete records may result in denial.
- Provide complete medical records when requested — letters or summaries alone are insufficient unless they contain all required detail.
- Retain documentation sufficient to demonstrate medical necessity and respond to BCBSNC requests in a timely manner to avoid denial risk.
Modifiers, Terms, and Threshold Definitions
Technical, Professional, and Global services modifiers
Modifier -26Professional component modifier (-26) indicates the professional (physician) component; verify allowance with the procedure code before use and do not append for global service.
Modifier -TCTechnical component modifier (-TC) indicates the technical component provided; verify allowance with the procedure code before use and do not append for global service.
Application guidanceConfirm that -26 or -TC are allowable for the specific procedure code prior to appending; do not append these modifiers when performing the global service.
Reference laboratory modifier
Modifier -90 definitionModifier -90 indicates the test was performed by a reference (outside) laboratory and must be added to the claim line when the service was referred to another party.
Usage constraintOnly independent clinical laboratories may append modifier -90 to denote services referred to an outside laboratory.
Reporting requirementWhen procedures are performed by parties other than the treating/provider, identify the laboratory procedure with modifier -90 on the claim line.
Repeat testing modifier
Modifier -91 purposeModifier -91 identifies repeat testing performed on the same day to obtain subsequent (multiple) test results when clinically necessary.
Non‑acceptable uses-91 may not be used to rerun tests to confirm initial results, for specimen or equipment problems, or when other codes describe series testing.
Clinical appropriatenessUse -91 only when repeat testing on the same day is clinically appropriate to obtain additional results, not for quality control or reruns.
CLIA‑waived testing modifier
QW modifier requirementCLIA‑waived tests must have the QW modifier appended to the procedure code.
ScopeThis requirement applies to all laboratory tests designated as CLIA‑waived under CLIA regulations.
Claim complianceFailure to append QW on CLIA‑waived tests may result in claim processing issues per policy guidelines.
Unit Threshold/Maximum units
Unit Threshold Met (operational)Unit Threshold Met (Daily and Historical) edits are invoked when units billed on a single DOS or over time exceed allowed reimbursement quantities without regard to individual clinical context.
Determination methodsMaximum units are set by CPT/HCPCS descriptions, medical policy guidelines, anatomical/clinical limits, analyses, or third‑party rules.
Claim outcomeIf reported units exceed the assigned maximum, the claim line is reimbursed only for units up to the allowed maximum.
81479 (unlisted molecular pathology)
When to use 81479CPT 81479 (unlisted molecular pathology) may be used only when there is no specific NGS procedure code that represents the requested test; maximum ONE unit may be billed.
Not for tests with specific codesIf a specific NGS panel code exists, that specific code must be reported instead of 81479.
Panel completeness and codingAll genes tested must be listed and incorrect coding for panels may result in denial of all submitted codes.
Multi-gene panel
DefinitionA multi‑gene panel is a defined panel of two or more genes assayed in parallel (NGS) for a specific condition; panels must contain genes specified in the AMA CPT code description.
Concurrent ordering prohibitionConcurrent ordering of multiple multi‑gene panels for the same specific condition is strictly prohibited; only one panel may be ordered at a time for that condition.
Repeat testing conditionsRepeat multi‑gene panel testing is allowed only if all conditions are met: patient met criteria, no previously identified causative mutation, and the requested panel contains one or more genes previously untested.
Policy Summary
PayerBlue Cross Blue Shield - North Carolina
PolicyLaboratory Procedures Medical Policy
Policy CodePolicy AHS - R2162
Change TypeCoding additions and clarification of panel and unit threshold rules
Effective DateMay 6, 2026
Last ReviewMay 6, 2026
Next Review DateJan 1, 2026
Key ActionSubmit outpatient laboratory claims per AMA CPT/HCPCS and ICD-10 guidelines and provide medical records when requested to support medical necessity.
SourceLink
On This Page
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.